Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study

Por Isambert, Nicolas, Hervieu, Alice, Rébé, Cedric, Hennequin, Audrey, Borg, Christophe, Zanetta, Sylvie, Chevriaux, Angélique, Richard, Corentin, Derangère, Valentin, Limagne, Emeric, Blanc, Julie, Bertaut, Aurélie, Ghiringhelli, François
Publicado no Oncoimmunology (2018)

Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial

Por Baig, Shanat, Veeranna, Vishy, Bolton, Shaun, Edwards, Nicola, Tomlinson, Jeremy W., Manolopoulos, Konstantinos, Moran, John, Steeds, Richard P., Geberhiwot, Tarekegn
Publicado no BMC Endocr Disord (2018)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Por Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Publicado em 2020-01-01

Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase...

Por Takano, Nao, Yamada, Suguru, Hirakawa, Akihiro, Yokoyama, Yukihiro, Kawashima, Hiroki, Maeda, Osamu, Okada, Tohru, Ohno, Eizaburo, Yamaguchi, Junpei, Ishikawa, Takuya, Sonohara, Fuminori, Suenaga, Masaya, Takami, Hideki, Hayashi, Masamichi, Niwa, Yukiko, Hirooka, Yoshiki, Ito, Yoshiyuki, Naganawa, Shinji, Ando, Yuichi, Nagino, Masato, Goto, Hidemi, Fujii, Tsutomu, Kodera, Yasuhiro
Publicado no Nagoya J Med Sci (2019)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Por Ma, Xinran, Li, Ling, Zhang, Lei, Fu, Xiaorui, Li, Xin, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Feng, Xiaoyan, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Zhang, Jieming, Li, Zhaoming, Zhang, Mingzhi
Publicado no Drug Des Devel Ther (2020)

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

Por Sakai, Daisuke, Chung, Hyun Cheol, Oh, Do-Youn, Park, Se Hoon, Kadowaki, Shigenori, Kim, Yeul Hong, Tsuji, Akihito, Komatsu, Yoshito, Kang, Yoon-Koo, Uenaka, Kazunori, Wijayawardana, Sameera R., Wacheck, Volker, Wang, Xuejing, Yamamura, Ayuko, Doi, Toshihiko
Publicado no Cancer Chemother Pharmacol (2017)

A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases

Por Zin W. Myint, Riham El Khouli, Bryan Lemieux, Donglin Yan, William H. St. Clair, Xiaoqi Liu, Charles A. Kunos
Publicado em 2022-04-01

RBTT-05. A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ABEMACICLIB...

Por Bagley, Stephen, Nasrallah, MacLean, O’Rourke, Donald, Hussain, Jasmin, Maloney-Wilensky, Eileen, Prior, Timothy, Brem, Steven, Desai, Arati
Publicado no Neuro Oncol (2019)

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with Oxaliplatin, Cisplatin, and Doxorubicin in Patients with Peritoneal Carcinomatosis: An Open-Label, Single-Arm, Phase II Clinical Trial

Por Michele De Simone, Marco Vaira, Monica Argenziano, Paola Berchialla, Alberto Pisacane, Armando Cinquegrana, Roberta Cavalli, Alice Borsano, Manuela Robella
Publicado em 2020-04-01

Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Por Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F
Publicado no Lancet (2016)

Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial

Por Criner, Gerard J., Delage, Antoine, Voelker, Kirk, Hogarth, D. Kyle, Majid, Adnan, Zgoda, Michael, Lazarus, Donald R., Casal, Roberto, Benzaquen, Sadia B., Holladay, Robert C., Wellikoff, Adam, Calero, Karel, Rumbak, Mark J., Branca, Paul R., Abu-Hijleh, Muhanned, Mallea, Jorge M., Kalhan, Ravi, Sachdeva, Ashutosh, Kinsey, C. Matthew, Lamb, Carla R., Reed, Michael F., Abouzgheib, Wissam B., Kaplan, Phillip V., Marrujo, Gregory X., Johnstone, David W., Gasparri, Mario G., Meade, Arturo A., Hergott, Christopher A., Reddy, Chakravarthy, Mularski, Richard A., Case, Amy Hajari, Makani, Samir S., Shepherd, Ray W., Chen, Benson, Holt, Gregory E.
Publicado no Am J Respir Crit Care Med (2019)

Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma...

Por Porta, Camillo, Calvo, Emiliano, Climent, Miguel A., Vaishampayan, Ulka, Osanto, Susanne, Ravaud, Alain, Bracarda, Sergio, Hutson, Thomas E., Escudier, Bernard, Grünwald, Viktor, Kim, Dennis, Panneerselvam, Ashok, Anak, Oezlem, Motzer, Robert J.
Publicado em 2012

A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer

Por Takashima, Tsutomu, Tokunaga, Shinya, Tei, Seika, Nishimura, Shigehiko, Kawajiri, Hidemi, Kashiwagi, Shinichiro, Yamagata, Shigehito, Noda, Satoru, Nishimori, Takeo, Mizuyama, Yoko, Sunami, Takeshi, Tezuka, Kenji, Ikeda, Katsumi, Ogawa, Yoshinari, Onoda, Naoyoshi, Ishikawa, Tetsuro, Kudoh, Shinzoh, Takada, Minoru, Hirakawa, Kosei
Publicado no Springerplus (2016)

Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study

Por Ravandi, Farhad, Assi, Rita, Daver, Naval, Benton, Christopher B, Kadia, Tapan, Thompson, Philip A, Borthakur, Gautam, Alvarado, Yesid, Jabbour, Elias J., Konopleva, Marina, Takahashi, Koichi, Kornblau, Steven, DiNardo, Courtney D., Estrov, Zeev, Flores, Wilmer, Basu, Sreyashi, Allison, James, Sharma, Padmanee, Pierce, Sherry, Pike, Allison, Cortes, Jorge E., Garcia-Manero, Guillermo, Kantarjian, Hagop M.
Publicado no Lancet Haematol (2019)

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Por Guo, J., Carvajal, R. D., Dummer, R., Hauschild, A., Daud, A., Bastian, B. C., Markovic, S. N., Queirolo, P., Arance, A., Berking, C., Camargo, V., Herchenhorn, D., Petrella, T. M., Schadendorf, D., Sharfman, W., Testori, A., Novick, S., Hertle, S., Nourry, C., Chen, Q., Hodi, F. S.
Publicado no Ann Oncol (2017)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

Por Nobuaki Kobayashi, Hisashi Hashimoto, Chisato Kamimaki, Ryo Nagasawa, Katsushi Tanaka, Sousuke Kubo, Seigo Katakura, Hao Chen, Nobuyuki Hirama, Ryota Ushio, Ayako Aoki, Kentaro Nakashima, Shuhei Teranishi, Saki Manabe, Hiroki Watanabe, Nobuyuki Horita, Keisuke Watanabe, Yu Hara, Masaki Yamamoto, Makoto Kudo, Hongmei Piao, Takeshi Kaneko
Publicado em 2020-08-01

Protocol for a phase 1 homeopathic drug proving trial

Por Teut, Michael, Hirschberg, Ute, Luedtke, Rainer, Schnegg, Cristoph, Dahler, Joern, Albrecht, Henning, Witt, Claudia M
Publicado em 2010

AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine...

Por Gareth Griffiths, Richard Fitzgerald, Thomas Jaki, Andrea Corkhill, Ellice Marwood, Helen Reynolds, Louise Stanton, Sean Ewings, Susannah Condie, Emma Wrixon, Andrea Norton, Mike Radford, Sara Yeats, Jane Robertson, Rachel Darby-Dowman, Lauren Walker, Saye Khoo, on behalf of the UK NIHR community
Publicado em 2020-06-01

Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial

Por Yamahara, Kenichi, Hamada, Akiko, Soma, Toshihiro, Okamoto, Rika, Okada, Masaya, Yoshihara, Satoshi, Yoshihara, Kyoko, Ikegame, Kazuhiro, Tamaki, Hiroya, Kaida, Katsuji, Inoue, Takayuki, Ohsugi, Yuko, Nishikawa, Hiroki, Hayashi, Hiroshi, Ito, Yoichi M, Iijima, Hiroaki, Ohnishi, Shunsuke, Hashimoto, Daigo, Isoe, Toshiyuki, Teshima, Takanori, Ogawa, Hiroyasu, Sato, Norihiro, Fujimori, Yoshihiro
Publicado no BMJ Open (2019)

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial

Por Yang, Lu, Yang, Sheng, Liu, Yutao, Li, Junling, Hu, Xingsheng, Wang, Yalei, Zhang, Yan, Wang, Yan
Publicado no Thorac Cancer (2018)